

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

INSIDE INFORMATION

LICENSE AGREEMENT WITH ROCHE

This announcement is made by Hansoh Pharmaceutical Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provision (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on October 16, 2025 (after trading hours), Shanghai Hansoh Biomedical Co., Ltd.* (上海翰森生物醫藥科技有限公司) and Changzhou Hansoh Pharmaceutical Co., Ltd.* (常州恒邦藥業有限公司) (collectively, the “**Licensors**”), both being wholly-owned subsidiaries of the Company, entered into a license agreement (the “**License Agreement**”) with F. Hoffmann-La Roche Ltd (the “**Licensee**”).

Under the License Agreement, the Licensors shall grant an exclusive worldwide license to the Licensee (excluding the Chinese Mainland, Hong Kong, Macau and Taiwan) to develop, manufacture and commercialize HS-20110 (the “**Product**”). The Licensors will receive an upfront payment of US\$80 million and be eligible to receive up to US\$1.45 billion in milestone payments associated with the development, regulatory approval and commercialization of the Product, as well as tiered royalties on potential future product sales.

The Product is an investigational CDH17-targeting antibody-drug conjugate (ADC) and is currently being developed for the treatment of colorectal cancer (CRC) and other solid tumors with a global Phase I trial underway in China and the United States.

The Licensee is a subsidiary of Roche Holding AG (“**Roche**”), which is listed on the SIX Swiss Exchange in Switzerland. Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics.

The Board believes that entering the License Agreement is in the best interests of the Company and its shareholders as a whole. The Company will also leverage on this opportunity to maximize the scientific and commercial value of the Group’s technology platforms.

LISTING RULES IMPLICATION

To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, the Licensee and its ultimate beneficial owner are independent of, and are not connected with, the Company and its connected persons (as defined in the Listing Rules). The transactions contemplated under the License Agreement are of a revenue nature in the ordinary and usual course of business of the Group and do not constitute any notifiable transactions or connected transactions of the Company under the Listing Rules.

The License Agreement is subject to necessary regulatory filings. The shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, October 17, 2025

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*